Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 5, 2026 · Material agreement · Investor press release · Financial statements
Seres Therapeutics, Inc.
10
Material agreement
Jun 5, 2026
| Item 1.01 | Entered a material definitive agreement |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Seres Therapeutics, Inc. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027 Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST net sales-based milestones Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability Clinical data from investigator-sponsored SER-155 study in immune checkpoint inh…
This filing reports Item 1.01 (entered a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Seres Therapeutics, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
